Loading...

ADL Bionatur Solutions

BST:041
Snowflake Description

Limited growth with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
041
BST
€75M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ADL Bionatur Solutions, S.A. provides prescription drugs and non-prescription products for food production animals and pets. The last earnings update was 172 days ago. More info.


Add to Portfolio Compare Print
  • ADL Bionatur Solutions has significant price volatility in the past 3 months.
041 Share Price and Events
7 Day Returns
-3.9%
BST:041
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
BST:041
-10.2%
DE Biotechs
-6%
DE Market
041 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ADL Bionatur Solutions (041) -3.9% -6.4% -7.6% - - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • No trading data on 041.
  • No trading data on 041.
Price Volatility
Industry
5yr Volatility vs Market

041 Value

 Is ADL Bionatur Solutions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ADL Bionatur Solutions. This is due to cash flow or dividend data being unavailable. The share price is €1.46.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ADL Bionatur Solutions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ADL Bionatur Solutions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:041 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.39
BME:ADL Share Price ** BME (2019-04-18) in EUR €1.91
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ADL Bionatur Solutions.

BST:041 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:ADL Share Price ÷ EPS (both in EUR)

= 1.91 ÷ -0.39

-4.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ADL Bionatur Solutions is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ADL Bionatur Solutions is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ADL Bionatur Solutions's expected growth come at a high price?
Raw Data
BST:041 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ADL Bionatur Solutions, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ADL Bionatur Solutions's assets?
Raw Data
BST:041 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.50
BME:ADL Share Price * BME (2019-04-18) in EUR €1.91
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
BST:041 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:ADL Share Price ÷ Book Value per Share (both in EUR)

= 1.91 ÷ 0.50

3.79x

* Primary Listing of ADL Bionatur Solutions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ADL Bionatur Solutions is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ADL Bionatur Solutions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ADL Bionatur Solutions has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

041 Future Performance

 How is ADL Bionatur Solutions expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
90.5%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is ADL Bionatur Solutions expected to grow at an attractive rate?
  • Unable to compare ADL Bionatur Solutions's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ADL Bionatur Solutions's earnings growth to the Germany market average as no estimate data is available.
  • ADL Bionatur Solutions's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:041 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:041 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 90.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:041 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:041 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 65 1
2018-12-31 28 1
BST:041 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 16 -14
2018-03-31 15 -13
2017-12-31 13 -12
2016-12-31 6 -3
2015-12-31 5 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ADL Bionatur Solutions is high growth as no earnings estimate data is available.
  • ADL Bionatur Solutions's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:041 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from ADL Bionatur Solutions Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:041 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
2018-12-31
BST:041 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30
2018-03-31
2017-12-31 -0.39
2016-12-31
2015-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ADL Bionatur Solutions will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ADL Bionatur Solutions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ADL Bionatur Solutions has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

041 Past Performance

  How has ADL Bionatur Solutions performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ADL Bionatur Solutions's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ADL Bionatur Solutions does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare ADL Bionatur Solutions's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ADL Bionatur Solutions's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ADL Bionatur Solutions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ADL Bionatur Solutions Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:041 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 16.41 -13.50 12.95
2018-03-31 14.81 -12.57 11.27
2017-12-31 13.21 -11.64 9.59
2016-12-31 6.13 -3.40 7.70
2015-12-31 4.67 -8.29 6.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ADL Bionatur Solutions has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ADL Bionatur Solutions has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ADL Bionatur Solutions improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ADL Bionatur Solutions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ADL Bionatur Solutions has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

041 Health

 How is ADL Bionatur Solutions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ADL Bionatur Solutions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ADL Bionatur Solutions's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • ADL Bionatur Solutions's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ADL Bionatur Solutions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ADL Bionatur Solutions Company Filings, last reported 9 months ago.

BST:041 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 18.18 17.88 1.99
2018-03-31 18.18 17.88 1.99
2017-12-31 15.01 27.03 5.07
2016-12-31 11.67 27.82 22.14
2015-12-31 15.10 4.52 0.77
  • ADL Bionatur Solutions's level of debt (98.3%) compared to net worth is high (greater than 40%).
  • Unable to establish if ADL Bionatur Solutions's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as ADL Bionatur Solutions has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on ADL Bionatur Solutions's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess ADL Bionatur Solutions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ADL Bionatur Solutions has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

041 Dividends

 What is ADL Bionatur Solutions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ADL Bionatur Solutions dividends.
If you bought €2,000 of ADL Bionatur Solutions shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ADL Bionatur Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ADL Bionatur Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:041 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:041 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ADL Bionatur Solutions has not reported any payouts.
  • Unable to verify if ADL Bionatur Solutions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ADL Bionatur Solutions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ADL Bionatur Solutions has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ADL Bionatur Solutions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ADL Bionatur Solutions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ADL Bionatur Solutions has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

041 Management

 What is the CEO of ADL Bionatur Solutions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pilar de la Huerta
CEO Bio

Ms. Pilar de la Huerta serves as Chief Executive Officer and Director of ADL Bionatur Solutions, S.A. She has been Member of Supervisory Board of Sygnis AG since July 7, 2017. Ms. de la Huerta served as the Co-Chief Executive Officer of Sygnis AG from March 31, 2013 to July 7, 2017, Chief Business Development Officer since March 1, 2017 and as its Member of Management Board until July 7, 2017. Ms. de la Huerta served as Chief Financial Officer of Sygnis AG from March 31, 2013 to March 1, 2017. Ms. de la Huerta served as the Chief Executive Officer of Genetrix S.L. and served as its Chairman. She served as the Chief Executive Officer of Sygnis Pharma AG since October 17, 2012 and served as its Member of Management Board. She joined Genetrix in 2010 from Viamed Salud where she was responsible for the R&D an New businesses area and was the Chief Executive Officer of Araclon Biotech, SL. Before of that, she served as Chief Executive Officer of Neuropharma and assumed different responsibilities within the Zeltia Group. With a massive experience in the biotechnology sector, she has assumed relevant responsibilities in biotech companies for the last 10 years. She has high value-added experience in formulating business structures and strategies, with direct experience in creating and managing companies in the biotech field. She has been a Member of Supervisory Board of Sygnis AG since July 7, 2017. Ms. de la Huerta served as a Director of Genetrix S.L. She served as a Director of Cellerix, S.A. She holds a Bachelor’s and Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.

CEO Compensation
  • Insufficient data for Pilar to compare compensation growth.
  • Insufficient data for Pilar to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Pilar de la Huerta

TITLE
CEO & Director

Juan Andrés Corrochano

TITLE
Chief Financial Officer

Manuel López Nieto

TITLE
Chief Technical Officer

Juan Jose Infante

TITLE
Chief Scientific Officer

Blanca San Román

TITLE
Investor Relations & Communication Director

Alicia del Corral

TITLE
Marketing Director

Víctor Infante

TITLE
Business Development Director & Director
Board of Directors

Ramón Betolaza

TITLE
Chairman
AGE
47

Pilar de la Huerta

TITLE
CEO & Director

Víctor Infante

TITLE
Business Development Director & Director

Emilio Moraleda Martínez

TITLE
Director

Juan Azcona de Arriba

TITLE
Director

Juan Fernando Naranjo Quintero

TITLE
Member of the Board of Directors

Carlos Tusquets Trias de Bes

TITLE
Member of the Board of Directors

José Manuel de la Infiesta Rollán

TITLE
Director

Juan Molins Monteys

TITLE
Director

Benito Damián Rubido Ramonde

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ADL Bionatur Solutions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ADL Bionatur Solutions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

041 News

Simply Wall St News

041 Company Info

Description

ADL Bionatur Solutions, S.A. provides prescription drugs and non-prescription products for food production animals and pets. Its product pipeline comprises BNT006, a peptide-based nutritional supplement to increase livestock productivity; BNT007, a recombinant multivalent VLP antigen; BNT010, a recombinant DIVA antigen; BNT015, a recombinant VLP antigen for the treatment of viral infection; and BNT005 vaccines. ADL Bionatur Solutions, S.A. has a strategic alliance with Nutricion Center NC to launch NC Microbiota products for weight control for various age groups that act as abdominal fat burners, body fat burners, fat blockers, drains, antioxidant-drainers, and appetite inhibitors, as well as complemented with specific probiotic strains for balancing the gut microbiome. The company was formerly known as Bioorganic Research and Services S.A. ADL Bionatur Solutions, S.A. is headquartered in Jerez de la Frontera, Spain.

Details
Name: ADL Bionatur Solutions, S.A.
041
Exchange: BST
Founded:
€75,233,117
39,389,067
Website: http://adlbionatur.com
Address: ADL Bionatur Solutions, S.A.
Avenida Antibióticos,59-61,
Leon,
Castile and León, 24009,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME ADL Social Shares Bolsas y Mercados Espanoles ES EUR 02. May 2018
BST 041 Social Shares Boerse-Stuttgart DE EUR 02. May 2018
Number of employees
Current staff
Staff numbers
314
ADL Bionatur Solutions employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 22:16
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2018/10/30
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.